Cure Today

Opdivo and Yervoy May Improve Survival for Resected Stage 3/4 Melanoma

Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure rate advantage ...
Cure Today

FDA Approves Opdivo Plus Yervoy For Some With Colorectal Cancer

FDA approves Opdivo and Yervoy for unresectable or metastatic MSI-H/dMMR colorectal cancer in patients 12 and older. Opdivo's accelerated approval for single-agent use in MSI-H/dMMR metastatic CRC is ...

Bristol Myers says Opdivo + Yervoy cut risk of relapse by 38% in colorectal cancer

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced ...
Monthly Prescribing Reference

Opdivo + Yervoy Approved as First-Line Tx for Hepatocellular Carcinoma

The immunotherapy combination significantly improved overall survival compared with lenvatinib or sorafenib. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination ...
Hosted on MSN

BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer

Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster immuno-oncology drug Opdivo (nivolumab) and Yervoy (ipilimumab) for a new cancer ...
Nasdaq

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib1 In the ...
Seeking Alpha

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High ...

Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...